Latest & greatest articles for fluoxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluoxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluoxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluoxetine

1. Fluoxetine versus other types of pharmacotherapy for depression. Full Text available with Trip Pro

Fluoxetine versus other types of pharmacotherapy for depression. Depression is common in primary care and is associated with marked personal, social and economic morbidity, thus creating significant demands on service providers. The antidepressant fluoxetine has been studied in many randomised controlled trials (RCTs) in comparison with other conventional and unconventional antidepressants. However, these studies have produced conflicting findings.Other systematic reviews have considered (...) selective serotonin reuptake inhibitor (SSRIs) as a group which limits the applicability of the indings for fluoxetine alone. Therefore, this review intends to provide specific and clinically useful information regarding the effects of fluoxetine for depression compared with tricyclics (TCAs), SSRIs, serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamineoxidase inhibitors (MAOIs) and newer agents, and other conventional and unconventional agents.To assess the effects of fluoxetine in comparison

2013 Cochrane

2. Fluoxetine

Fluoxetine Top results for fluoxetine - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluoxetine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK

Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Lenox-Smith A, Greenstreet L, Burslem K, Knight C Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of venlafaxine versus either generic fluoxetine or generic amitriptyline for the first-line treatment of patients with major depressive disorder. The authors concluded that, despite its relatively high

2009 NHS Economic Evaluation Database.

4. ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis Full Text available with Trip Pro

ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis The burden of major depressive disorder includes suffering due to symptom severity, functional impairment, and quality of life deficits. The aim of this study was to compare the differences between electroconvulsive therapy and pharmacotherapy in reducing such burdens.This was a pooled analysis study including 2 open-label trials for major (...) depressive disorder inpatients receiving either standard bitemporal and modified electroconvulsive therapy with a maximum of 12 sessions or 20 mg/d of fluoxetine for 6 weeks. Symptom severity, functioning, and quality of life were assessed using the 17-item Hamilton Rating Scale for Depression, the Modified Work and Social Adjustment Scale, and SF-36. Side effects following treatment, including subjective memory impairment, nausea/vomiting, and headache, were recorded. The differences between these 2

2017 International Journal of Neuropsychopharmacology

5. Fluoxetine

Fluoxetine Fluoxetine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Fluoxetine Fluoxetine Aka: Fluoxetine , Prozac , Prozac Weekly (...) on the sedation to excitation continuum Most activation or aggravation of all s Anxiety or nervousness Consider ( ) at bedtime Avoid in the elderly Weight loss may occur X. Adverse Effects: Pregnancy Earlier safety data Major Fetal Structural abnormality No Change (5.5% versus 4% for ) Minor Fetal Structural abnormality Significant Association (15.5% vs 6.5% for ) Fluoxetine also associated with NICU admissions Low birth weight References: Study of n=482 Safety data in 2015 Fluoxetine has been well studied

2018 FP Notebook

6. Olanzapine, but Not Fluoxetine, Treatment Increases Survival in Activity-Based Anorexia in Mice. Full Text available with Trip Pro

Olanzapine, but Not Fluoxetine, Treatment Increases Survival in Activity-Based Anorexia in Mice. Anorexia nervosa (AN) is an eating disorder characterized by extreme hypophagia, hyperactivity, and fear of weight gain. No approved pharmacological treatments exist for AN despite high mortality rates. The activity-based anorexia (ABA) phenomenon models aspects of AN in rodents, including progressive weight loss, reduced food intake, and hyperactivity. First, we optimized the ABA paradigm for mice (...) with fluoxetine (4 weeks) or subchronic treatment with olanzapine (OLZ) (1 week) on ABA in BALB/cJ mice. OLZ (12 mg/kg/day) significantly increased survival and reduced food anticipatory activity (FAA). However, OLZ did not alter food intake or running wheel activity during ad-lib feeding (baseline) or restriction conditions, or in mice housed without wheels. Fluoxetine (18 mg/kg/day) increased food intake and reduced FAA, but did not alter survival. Here, we report for the first time that OLZ

2012 Neuropsychopharmacology

7. Hypersexuality: fluoxetine

Hypersexuality: fluoxetine Hyperse Hypersexuality: fluo xuality: fluox xetine etine Evidence summary Published: 21 July 2015 nice.org.uk/guidance/esuom46 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in July 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Summary No randomised controlled trials (RCTs) which evaluate the use (...) of fluoxetine in the treatment of hypersexuality were found, nor any studies that compared fluoxetine with any of the hormonal treatments licensed to treat hypersexuality. Limited evidence from 3 small, short-term observational studies suggests that fluoxetine may improve some measurements of hypersexuality and sexual preoccupation in men who have either been convicted of a sexual offence or who have a paraphilia or a non-paraphilic sexual addiction. However, these studies had a number of limitations which

2015 National Institute for Health and Clinical Excellence - Advice

8. Effectiveness of cognitive behavioral therapy and fluoxetine on sexual function of women with obsessive compulsive disorder: A double-blind randomized controlled trial. Full Text available with Trip Pro

Effectiveness of cognitive behavioral therapy and fluoxetine on sexual function of women with obsessive compulsive disorder: A double-blind randomized controlled trial. Obsessive compulsive disorder (OCD) is a mental health concern due to its various negative consequences, especially in sexual function. Therefore, the treatment of sexual dysfunction in women with OCD is important in order to improve the patient's marital function and mental health.To compare the sexual behavior and sexual (...) and marital satisfaction in women with obsessive-compulsive disorder (OCD) before and after treatment with fluoxetine and cognitive behavior therapy.This randomized clinical trial was conducted at psychiatric and psychological counseling centers in Kashan (Iran) from January 2, 2014, to December 29, 2014. Fifty-eight women with OCD were included in the study. In order to compare the effectiveness of pharmacological treatment (fluoxetine) and psychological treatment, cognitive behavior therapy (CBT), 58

2017 Electronic physician Controlled trial quality: uncertain

9. Comparison among clomipramine, fluoxetine, and placebo for the treatment of anxiety disorders in children and adolescents. Full Text available with Trip Pro

Comparison among clomipramine, fluoxetine, and placebo for the treatment of anxiety disorders in children and adolescents. The purpose of this study was to test the efficacy of clomipramine and fluoxetine, controlled by placebo, and compare their action in children and adolescents with anxiety disorders.Thirty subjects (ages 7-17 years), who were diagnosed with generalized anxiety disorder and/or separation anxiety disorder and/or social phobia, were submitted to a 12 week double-blind (...) , randomized, placebo-controlled trial of clomipramine and fluoxetine. The instruments included: the Schedule for Affective Disorders and Schizophrenia, the Multidimensional Anxiety Scale for Children, the Children's Depression Inventory, the Clinical Global Impressions, and the Children's Global Assessment Scale.All groups (clomipramine [n=9], fluoxetine [n=10], placebo [n=11]) showed a significant improvement after 12 weeks of treatment. There were significant differences between the fluoxetine

2013 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: uncertain

10. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation

The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation Kongsakon R, Bunchapattanasakda C Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of escitalopram versus fluoxetine and venlafaxine for the treatment of major depressive disorder. The authors concluded that escitalopram was more

2008 NHS Economic Evaluation Database.

11. Fluoxetine

Fluoxetine USE OF FLUOXETINE IN PREGNANCY 0344 892 0909 USE OF FLUOXETINE IN PREGNANCY (Date of issue: January 2017 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used (...) in the treatment of depression, obsessive-compulsive disorder and bulimia nervosa. The majority of studies have demonstrated no statistically significant increase in overall risk of any malformation, with only one cohort study and two meta-analyses which combined the same primary data suggesting a slight increase in occurrence. Data concerning the risk of cardiac malformation following fluoxetine use in early pregnancy are conflicting, and whilst most studies have shown no association, three cohort studies

2014 UK Teratology Information Service

12. 12-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression

12-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression 16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. 16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression (FLAME) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02389712 Recruitment Status : Completed First Posted : March 17, 2015 Last Update Posted : May 24, 2018 Sponsor: Mayo Clinic

2015 Clinical Trials

13. Continuation-phase cognitive therapy and fluoxetine are effective in reducing the risk of relapse/recurrence in major depression after incomplete remission

Continuation-phase cognitive therapy and fluoxetine are effective in reducing the risk of relapse/recurrence in major depression after incomplete remission Continuation-phase cognitive therapy and fluoxetine are effective in reducing the risk of relapse/recurrence in major depression after incomplete remission | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continuation-phase cognitive therapy and fluoxetine are effective in reducing

2014 Evidence-Based Mental Health

14. Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression

Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression Article Text Aetiology Fluoxetine

2012 Evidence-Based Mental Health

15. Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder

Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine

2010 Evidence-Based Mental Health

16. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. (Abstract)

Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Antidepressants are often used to treat chronic daily headache disorders such as transformed migraine, in part because of the high prevalence of associated mood disorder. We conducted this study to evaluate the efficacy and tolerability of combined treatment with amitriptyline and fluoxetine compared with amitriptyline alone for chronic daily headache due (...) to transformed migraine.Thirty-nine patients, 26 women and 13 men, aged 20 to 69 years (mean, 36.4; SD, 2.5) who fulfilled criteria for transformed migraine proposed by Silberstein et al were studied prospectively. Amitriptyline was dosed as follows: 8 mg/day for 6 days, 8 mg twice a day for 6 days, 20 mg/day for 6 days, and 20 mg twice a day for 45 days. In the group receiving combination therapy, fluoxetine was dosed and administered identically. The initial and end of the study (9 weeks) headache indices

2002 Headache Controlled trial quality: uncertain

17. Fluoxetine's effect on weight loss in obese subjects. (Abstract)

Fluoxetine's effect on weight loss in obese subjects. Forty-five obese subjects with a mean weight of 102.9 kg and a body mass index (in kg/m2) of 37.6 were randomly assigned to a fluoxetine-diet group (n = 23) or a placebo-diet group (n = 22) for 52 wk. At week 29, 14 subjects on fluoxetine who completed the study attained their maximum weight loss of 12.4 kg, an amount significantly greater than the maximum weight loss of 4.5 kg for the 16 on placebo who completed the study. The fluoxetine (...) group's significantly greater mean weight loss continued through week 45. However, those on fluoxetine regained a mean of 4.2 kg from their lowest weight (P less than 0.001) whereas the placebo group did not. By the end of the study, each group weighed significantly less than they did at baseline (fluoxetine: -8.2 kg; placebo: -4.5 kg; P less than 0.05) although the difference between groups was no longer significant (P greater than 0.05). Several factors were considered as possible causes

1991 The American journal of clinical nutrition Controlled trial quality: uncertain

18. Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)

Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD) Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Fluoxetine vs EMDR (...) provided by: Boston University Study Details Study Description Go to Brief Summary: The purpose of this study is to compare two treatments for post-traumatic stress disorder (PTSD): fluoxetine (an antidepressant) and Eye Movement Desensitization and Reprocessing (EMDR, a psychological treatment in which the patient is led through the memory of a traumatic experience in order to heal him/herself). There are a variety of therapies used to treat PTSD, but the effectiveness of medication alone vs

1999 Clinical Trials

19. Does fluoxetine improve recovery after stroke? (Abstract)

Does fluoxetine improve recovery after stroke? The studyFOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 2019;393:256-74.The study was funded by the UK Stroke Association and the NIHR Health Technology Assessment Programme project number 13/04/30.To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000729/a-commonly-used-antidepressant-doesnt-improve

2019 BMJ Controlled trial quality: predicted high

20. Fluoxetine

Fluoxetine Fluoxetine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Fluoxetine Fluoxetine Aka: Fluoxetine , Prozac , Prozac Weekly (...) on the sedation to excitation continuum Most activation or aggravation of all s Anxiety or nervousness Consider ( ) at bedtime Avoid in the elderly Weight loss may occur X. Adverse Effects: Pregnancy Earlier safety data Major Fetal Structural abnormality No Change (5.5% versus 4% for ) Minor Fetal Structural abnormality Significant Association (15.5% vs 6.5% for ) Fluoxetine also associated with NICU admissions Low birth weight References: Study of n=482 Safety data in 2015 Fluoxetine has been well studied

2015 FP Notebook